MedTrace Logo

An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery

NCT02772718 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-05-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and clinical pharmacology of XOMA 358 in patients with hypoglycemia after gastric bypass surgery.

Conditions

Interventions

DRUG

XOMA 358 single dose level A

XOMA 358 single dose level A administered by intravenous infusion

DRUG

XOMA 358 single dose level B

XOMA 358 single dose level B administered by an intravenous infusion

DRUG

XOMA 358 single dose level C

XOMA 358 single dose level C administered by an intravenous infusion

DRUG

XOMA 358 multiple dose level 1

XOMA 358 multiple dose level 1 administered by an intravenous infusion

Sponsors & Collaborators

  • XOMA (US) LLC

    lead INDUSTRY

Principal Investigators

  • Allan Gordon, MD, PhD · XOMA (US) LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2021-05-31
Completion
2021-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02772718 on ClinicalTrials.gov